Latest news with #SeriesC
Yahoo
2 days ago
- Business
- Yahoo
Sustainability platform Watershed launches free global emissions database
This story was originally published on ESG Dive. To receive daily news and insights, subscribe to our free daily ESG Dive newsletter. Watershed, a sustainability software startup, has launched a free version of its global emissions database, the Comprehensive Environmental Data Archive, to help companies 'address critical gaps in emissions reporting data to inform more impactful climate action.' The startup — which helps companies measure, report and reduce their carbon footprint — unveiled Open CEDA last week and said the database covers 148 countries, 400 industries and 95% of the global gross domestic product. Open CEDA considers 60,000 emissions factors when evaluating a company's footprint, provides annual updates on a company's decarbonization progress and measures emissions in compliance with the GHG protocol, per its website. Watershed's platform takes data directly from companies' systems to create an 'audit-ready' carbon footprint report and supports businesses in understanding their climate disclosure obligations. The sustainability startup currently manages around 1 gigatonnes of carbon dioxide equivalent across its portfolio, according to its website, which is almost double the volume it was managing last year. Watershed had reported managing around 479 million tonnes of carbon equivalent in February 2024. The company has a 2030 goal of collaborating with its customers to reduce or remove 500 megatonnes of carbon dioxide equivalent from the atmosphere, which accounts for nearly 1% of annual global emissions. Watershed's current client list includes BlackRock, Bain Capital, Carlyle, KKR, Visa, Walmart, FedEx, Etsy, Paramount and others. 'Simply put, better data leads to better decisions,' Watershed Co-Founder Christian Anderson said in a May 22 release. 'By opening up CEDA to the public, we hope to give organizations of all sizes a more accurate foundation from which to make critical choices about their sustainability action.' Watershed said it will continue to offer clients a paid version of CEDA as well. The version includes additional features, such as breakdown of emissions categorized by scopes 1, 2 and 3, and a comprehensive analysis that helps companies understand differences in emission factors, among other offerings. The company said Open CEDA is recommended for 'organizations or companies measuring for the first time,' whereas CEDA is recommended for 'more advanced sustainability programs and service providers,' per its website. Last year, Watershed secured $100 million during a Series C funding round, which it said would allow it to continue developing climate programs for clients and redouble its investments in Europe. The financing was led by San Francisco-based investment firm Greenoaks and raised the company's valuation to $1.8 billion at the time. Recommended Reading Climate software startup Watershed clinches $100M in funding
Yahoo
3 days ago
- Business
- Yahoo
Joby Aviation, Inc. (JOBY) Soars Almost 29% After Securing $250 Million Investment from Toyota
Joby Aviation, Inc. (NYSE:JOBY) stock surged significantly on Wednesday after the electric air taxi developer announced it had received a $250 million investment from Toyota. This funding is part of a previously disclosed $500 million commitment from the automaker, aimed at helping Joby Aviation, Inc. (NYSE:JOBY) move closer to certification and large-scale production of its electric air taxis. Toyota initially revealed the investment plan in October. Joby specializes in electric vertical takeoff and landing aircraft, or eVTOLs, which operate similarly to helicopters. The technology is designed to help ease urban traffic and lower emissions. The new funding adds to Toyota's earlier $394 million investment in Joby during a Series C funding round in 2020. Toyota North America CEO Tetsuo Ogawa joined Joby's board in July 2023, and the company has had a Toyota representative on its board since 2020. CEO and founder of Joby Aviation, Inc. (NYSE:JOBY), JoeBen Bevirt, made the following comment in the release: 'We're already seeing the benefit of working with Toyota in streamlining manufacturing processes and optimizing design. This is an important next step in our alliance with Toyota to scale the promise of electric flight.' Joby Aviation, Inc. (NYSE:JOBY) closed nearly 29% higher on May 28. While we acknowledge the potential of JOBY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JOBY and that has 100x upside potential, check out our report about this cheapest AI stock. READ MORE: and Disclosure. None.
Yahoo
23-05-2025
- Business
- Yahoo
Hinge Health just broke open the digital health IPO market. Here's who's getting rich.
Hinge Health just went public in a watershed moment for the digital health industry. Its shares popped Thursday, jumping to over $39 a share, up 23% from its IPO price. Here's what Hinge Health's major investors' stakes are worth after its IPO. Physical therapy startup Hinge Health finally went public Thursday in a watershed moment for the digital health market. Hinge Health's stock price popped after debuting on the New York Stock Exchange, soaring to $39.25 per share, 23% above its initial public offering price of $32 a share. The $32 IPO share price valued Hinge Health at about $2.6 billion, based on shares outstanding after the IPO. At the market close, however, the company was worth about $3 billion. It's a strong start for Hinge Health's public market debut, and the first true glimmer of hope for the digital health IPO market in years. The last wave of healthcare public market exits, in 2021, saw 23 healthcare companies go public via IPO or SPAC. In the following three years, only four healthcare companies went public. Only two of those, Waystar and Tempus AI, are still trading on the stock market. Hinge Health, founded in 2014 to provide virtual care for musculoskeletal conditions, was forced to consider a delay for its IPO plans in early April after President Donald Trump announced sweeping tariffs on imported goods from other countries, causing a sharp drop in the stock market. It resumed those efforts publicly this month as the market stabilized. Hinge Health raised $437 million in the IPO, which included $273 million in proceeds to the company and $164 million to its selling shareholders. Hinge Health's $2.6 billion IPO valuation is a 52% markdown from its last private valuation of $6.2 billion. It notched that valuation in a 2021 $400 million Series E round co-led by Tiger Global and Coatue Management. We don't know what Hinge Health's investors paid for their shares, so we can't calculate their profit. However, since Hinge Health's shares opened on the stock market at $39.25, we used that price to determine the worth of their stakes. Here's what the stakes of all of Hinge Health's major investors and executives are worth after the IPO. Insight Partners, an investor: $433 million Venture capital and private equity firm Insight Partners owns the largest stake in Hinge Health with about 12.3 million shares, or 13.7% of the company. The firm led Hinge Health's $26 million Series B fundraise in 2018. Teddie Wardi, a managing director at Insight Partners, has served on Hinge Health's board of directors since the firm's investment. Insight Partners later participated in Hinge Health's Series C and D rounds in 2020 and 2021, respectively. Insight Partners sold 1.25 million shares in Hinge Health's IPO, which at the $32 IPO price would have brought in $40 million. At the $39.25 market debut price, the firm's remaining stake is worth about $433 million. Daniel Perez, cofounder and CEO: $414 million Daniel Perez's first encounter with physical therapy came after a bike crash when he was 13 years old, which forced him to undergo three surgeries and 12 months of rehabilitation. He started Hinge Health alongside executive chairman Gabriel Mecklenburg to improve the accessibility of musculoskeletal care and reduce the specialty's reliance on surgeries and opioids. Hinge Health is Perez and Mecklenburg's third venture, after the Oxbridge Biotech Roundtable, which aimed to bridge the gap between life sciences academia and markets, and Marblar, a platform designed to generate commercial uses for scientific discoveries. Perez is Hinge Health's largest individual shareholder. He owns about 10.6 million shares, or 13.1% of the company. He didn't sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $414 million. Atomico, an investor: $309 million Atomico is a London-based venture firm started in 2006 by Skype cofounder Niklas Zennström. The firm led Hinge Health's $8 million Series A in 2017, when the startup was based in London. (Hinge Health moved its headquarters to San Francisco the same year.) Atomico later participated in Hinge Health's Series B, C, and D funding rounds. Atomico owns about 7.9 million shares, or 9.8% of the company. The firm sold 1,497,546 shares in the IPO, which at the IPO price of $32 would have brought in about $48 million. At the $39.25 market debut price, the firm's remaining stake is worth about $309 million. Tiger Global, an investor: $207 million Investment firm Tiger Global first backed Hinge Health in 2021, co-leading its $300 million Series D alongside Coatue Management. In October of that year, Tiger Global also co-led the company's $400 million Series E, also alongside Coatue. The $400 million Series E round boosted Hinge Health to the $6.2 billion valuation that Hinge Health was forced to slash in its IPO. Tiger Global has drawn criticism in recent years for backing startups at extraordinarily high valuations, particularly during 2021's venture investment peak. Tiger Global owns about 5.3 million shares, or 6.5% of the company. The firm sold 258,183 shares in the IPO, which at the IPO price of $32 would have brought in about $8.3 million. At the $39.25 market debut price, the firm's remaining stake is worth about $207 million. Coatue Management, an investor: $185 million New York-based Coatue Management invests across all private and public fundraising stages, with venture capital, private equity, and hedge fund management units. The firm co-led Hinge Health's $300 million Series D alongside Tiger Global in January 2021, then co-led its $400 million Series E with Tiger Global that October. Hinge Health's S-1 filing notes that Coatue will sell $50 million in Series E preferred shares back to the company immediately before Hinge's IPO. That agreement was created in February, per the filing. The company didn't share a reason for the stock repurchase. Coatue owns about 4.7 million shares of common stock, or 5.8% of the company. The firm didn't sell any shares in the IPO. At the $39.25 market debut price, the firm's stake is worth about $185 million. 11.2 Capital, an investor: $169 million San Francisco-based 11.2 Capital backs early-stage tech startups and wrote one of the first checks into Hinge Health. The firm led Hinge Health's seed round in 2016, and invested further in its Series A, B, C, and D rounds, according to the firm. 11.2 Capital owns about 4.3 million shares, or 5.4% of Hinge Health. The firm sold 788,691 shares in the IPO, which at the IPO price of $32 would have brought in about $25 million. At the $39.25 market debut price, the firm's remaining stake is worth about $169 million. Bessemer Venture Partners, an investor: $161 million Bessemer Venture Partners backs early-stage and growth-stage startups through venture and private equity investments. The firm has more than 300 companies in its portfolio, according to its website. Bessemer led Hinge Health's $90 million Series C in February 2020. Bessemer partner Elliott Robinson has served on Hinge Health's board of directors since that round. The firm also participated in Hinge Health's $300 million Series D round in January 2021. Bessemer Venture Partners owns about 4.1 million shares, or 5.1% of the company. The firm sold 725,066 shares in the IPO, which at the IPO price of $32 would have brought in about $24 million. At the $39.25 market debut price, its remaining stake is worth about $161 million. Gabriel Mecklenburg, cofounder and executive chairman: $158 million Gabriel Mecklenburg cofounded Hinge Health alongside Perez, personally inspired by the months of physical therapy he completed after tearing his ACL in a judo sparring session. Mecklenburg served as the company's COO for six years. It was a familiar role for him; he'd held the COO title at the two companies he started with Perez before Hinge Health, Oxbridge Biotech Roundtable and Marblar. In 2021, he transitioned to his current role of executive chairman. In addition to his work with Hinge Health, he's served on the board of addiction care startup Pelago since 2022. Mecklenburg owns about 4 million shares, or 4.9% of the company. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $158 million. IP2IPO, an investor: $42 million IP2IPO, named IP2IPO Portfolio LP in Hinge Health's S-1, specializes in moving innovative technologies, talent, and intellectual property from academic institutions to commercial industries. Both Perez and Mecklenburg stepped away from pursuing higher education degrees to build Hinge Health. Perez was taking a leave of absence from a Ph.D. program in biochemistry at the University of Oxford, while Mecklenburg was researching musculoskeletal regenerative medicine at Imperial College London. IP2IPO is a subsidiary of IP Group, a London-based firm that backs breakthrough science and tech companies. IP Group says it's the founding investor in Hinge Health. The firm told BI it actually invested in Marblar, Perez and Mecklenburg's previous startup, back in 2012. That investment rolled over into Hinge Health. "As the UK's leading investor in university spinouts, we met Dan whilst he was in Oxford, working on brilliant ideas and showing real entrepreneurial spirit and tenacity," said Robert Trezona, a partner at IP Group. He said IP Group invested around £1 million, or about $1.12 million at the time, shortly after meeting Perez. IP2IPO owns about 1.1 million shares, or 1.3% of the company. The firm sold about 47,000 shares in the IPO, which at the IPO price of $32 would have brought in about $1.5 million. At the $39.25 market debut price, its remaining stake would be worth about $42 million. Heuristic Capital, an investor: $40 million Early-stage VC firm Heuristic Capital was founded in 2016, and first invested in Hinge Health's seed round that same year. The Santa Clara, California-based firm then invested in Hinge Health's four subsequent raises, from Hinge Health's Series A to its Series D. Heuristic Capital told BI that the Hinge Health team worked out of the firm's San Francisco office in the startup's early days, moving into an independent office in the Bay Area after successfully closing a Series A round. The firm owns about 1 million shares of Hinge Health, or 1.3% of the company. It sold 194,305 shares in the IPO, which at the initial share price of $32 would have brought in about $6.2 million. At the $39.25 market debut price, its remaining stake would be worth about $40 million. Jim Pursley, president: $24 million Longtime digital health executive Jim Pursley joined Hinge Health as its president in 2021. He'd previously worked with the Hinge Health team as an advisor from 2017 to 2019. Pursley came to Hinge Health from Livongo, where he spent six years as the diabetes company's chief commercial officer through its 2019 IPO. He left the company shortly after Livongo announced its $18.5 billion acquisition by Teladoc in 2020. He also held leadership roles at GE Healthcare and Care Innovations, a joint venture between Intel and GE. In addition to his role at Hinge Health, he serves as an independent board member at digital therapeutics company Bodyport. Pursley owns about 604,665 shares. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $24 million. The Vertical Group, an investor: $22 million The Vertical Group, named in Hinge Health's S-1 as Vertical GP-8, is a Basking Ridge, New Jersey-based firm that invests in healthcare and biotech companies. Vertical invested in Hinge Health's seed and Series A funding rounds, according to the firm. The firm told BI that it previously sold a portion of its Hinge Health shares in a secondary transaction in 2021, at $77 a share, and another portion in a 2023 secondary sale, at $36 a share. Vertical is also an investor in diabetes care startup Omada Health, according to the firm's website. Omada is the only other digital health company to file to go public so far this year. Vertical GP-8 owns 554,919 shares. The firm sold about 106,000 shares in the IPO, which at the IPO price of $32 would have brought in about $3.4 million. At the $39.25 market debut price, the firm's remaining stake is worth about $22 million. Jon Reynolds, an angel investor: $14 million Jon Reynolds is the cofounder and former CEO of SwiftKey, the AI-powered keyboard app acquired by Microsoft in 2016. He told BI he first backed Hinge Health that same year, participating in the startup's seed and seed extension funding rounds. Reynolds owned about 360,175 shares. He sold 68,605 shares in the IPO, which at the IPO price of $32 would have brought in about $2.2 million. At the $39.25 market debut price, his remaining stake is worth about $14 million. Industry Ventures, an investor: $12 million San Francisco-based Industry Ventures makes VC bets using flexible capital structures, including secondary transactions and buyouts. Hinge Health has never publicly announced a secondary transaction made by Industry Ventures. Hinge Health's S-1 specifies that Industry Ventures invested in the company through its Secondary IX fund, which the firm announced in March 2021. Industry Ventures didn't respond to a request for comment from BI. Industry Ventures owns 307,259 shares. The firm sold 58,526 shares in the IPO, which at the initial share price of $32 would have brought in about $1.9 million. At the $39.25 market debut price, its remaining stake is worth about $12 million. James Budge, CFO: $6.8 million Serial CFO James Budge joined Hinge Health as its finance chief in 2023. According to his LinkedIn, he's been the CFO of at least eight other companies, spanning industries from workforce software to entertainment tech. He's also served on the board of directors of healthtech company Shadowbox since 2022. Budge owns 172,241 shares. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $6.8 million. Kristina Leslie, board member: $343,000 Kristina Leslie joined Hinge Health's board of directors in May 2024 as its audit chair. Leslie, the former CFO of Dreamworks Animation, has spent nearly two decades serving on various company boards, including Glassdoor, CVB Financial Corp., and Rover. According to her LinkedIn, she currently sits on the boards of Sunstone Hotel Investors and Justworks and chairs the board of directors of Blue Shield of California. Leslie owns 8,750 shares. She did not sell any shares in the IPO. At the $39.25 market debut price, her stake is worth about $343,000. Read the original article on Business Insider
Yahoo
22-05-2025
- Business
- Yahoo
Hinge Health just broke open the digital health IPO market. Here's who's getting rich.
Hinge Health just went public in a watershed moment for the digital health industry. Its shares popped Thursday, jumping to over $39 a share, up 23% from its IPO price. Here's what Hinge Health's major investors' stakes are worth after its IPO. Physical therapy startup Hinge Health finally went public Thursday in a watershed moment for the digital health market. Hinge Health's stock price popped after debuting on the New York Stock Exchange, soaring to $39.25 per share, 23% above its initial public offering price of $32 a share. The $32 IPO share price valued Hinge Health at about $2.6 billion, based on shares outstanding after the IPO. At the market close, however, the company was worth about $3 billion. It's a strong start for Hinge Health's public market debut, and the first true glimmer of hope for the digital health IPO market in years. The last wave of healthcare public market exits, in 2021, saw 23 healthcare companies go public via IPO or SPAC. In the following three years, only four healthcare companies went public. Only two of those, Waystar and Tempus AI, are still trading on the stock market. Hinge Health, founded in 2014 to provide virtual care for musculoskeletal conditions, was forced to consider a delay for its IPO plans in early April after President Donald Trump announced sweeping tariffs on imported goods from other countries, causing a sharp drop in the stock market. It resumed those efforts publicly this month as the market stabilized. Hinge Health raised $437 million in the IPO, which included $273 million in proceeds to the company and $164 million to its selling shareholders. Hinge Health's $2.6 billion IPO valuation is a 52% markdown from its last private valuation of $6.2 billion. It notched that valuation in a 2021 $400 million Series E round co-led by Tiger Global and Coatue Management. We don't know what Hinge Health's investors paid for their shares, so we can't calculate their profit. However, since Hinge Health's shares opened on the stock market at $39.25, we used that price to determine the worth of their stakes. Here's what the stakes of all of Hinge Health's major investors and executives are worth after the IPO. Insight Partners, an investor: $433 million Venture capital and private equity firm Insight Partners owns the largest stake in Hinge Health with about 12.3 million shares, or 13.7% of the company. The firm led Hinge Health's $26 million Series B fundraise in 2018. Teddie Wardi, a managing director at Insight Partners, has served on Hinge Health's board of directors since the firm's investment. Insight Partners later participated in Hinge Health's Series C and D rounds in 2020 and 2021, respectively. Insight Partners sold 1.25 million shares in Hinge Health's IPO, which at the $32 IPO price would have brought in $40 million. At the $39.25 market debut price, the firm's remaining stake is worth about $433 million. Daniel Perez, cofounder and CEO: $414 million Daniel Perez's first encounter with physical therapy came after a bike crash when he was 13 years old, which forced him to undergo three surgeries and 12 months of rehabilitation. He started Hinge Health alongside executive chairman Gabriel Mecklenburg to improve the accessibility of musculoskeletal care and reduce the specialty's reliance on surgeries and opioids. Hinge Health is Perez and Mecklenburg's third venture, after the Oxbridge Biotech Roundtable, which aimed to bridge the gap between life sciences academia and markets, and Marblar, a platform designed to generate commercial uses for scientific discoveries. Perez is Hinge Health's largest individual shareholder. He owns about 10.6 million shares, or 13.1% of the company. He didn't sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $414 million. Atomico, an investor: $309 million Atomico is a London-based venture firm started in 2006 by Skype cofounder Niklas Zennström. The firm led Hinge Health's $8 million Series A in 2017, when the startup was based in London. (Hinge Health moved its headquarters to San Francisco the same year.) Atomico later participated in Hinge Health's Series B, C, and D funding rounds. Atomico owns about 7.9 million shares, or 9.8% of the company. The firm sold 1,497,546 shares in the IPO, which at the IPO price of $32 would have brought in about $48 million. At the $39.25 market debut price, the firm's remaining stake is worth about $309 million. Tiger Global, an investor: $207 million Investment firm Tiger Global first backed Hinge Health in 2021, co-leading its $300 million Series D alongside Coatue Management. In October of that year, Tiger Global also co-led the company's $400 million Series E, also alongside Coatue. The $400 million Series E round boosted Hinge Health to the $6.2 billion valuation that Hinge Health was forced to slash in its IPO. Tiger Global has drawn criticism in recent years for backing startups at extraordinarily high valuations, particularly during 2021's venture investment peak. Tiger Global owns about 5.3 million shares, or 6.5% of the company. The firm sold 258,183 shares in the IPO, which at the IPO price of $32 would have brought in about $8.3 million. At the $39.25 market debut price, the firm's remaining stake is worth about $207 million. Coatue Management, an investor: $185 million New York-based Coatue Management invests across all private and public fundraising stages, with venture capital, private equity, and hedge fund management units. The firm co-led Hinge Health's $300 million Series D alongside Tiger Global in January 2021, then co-led its $400 million Series E with Tiger Global that October. Hinge Health's S-1 filing notes that Coatue will sell $50 million in Series E preferred shares back to the company immediately before Hinge's IPO. That agreement was created in February, per the filing. The company didn't share a reason for the stock repurchase. Coatue owns about 4.7 million shares of common stock, or 5.8% of the company. The firm didn't sell any shares in the IPO. At the $39.25 market debut price, the firm's stake is worth about $185 million. 11.2 Capital, an investor: $169 million San Francisco-based 11.2 Capital backs early-stage tech startups and wrote one of the first checks into Hinge Health. The firm led Hinge Health's seed round in 2016, and invested further in its Series A, B, C, and D rounds, according to the firm. 11.2 Capital owns about 4.3 million shares, or 5.4% of Hinge Health. The firm sold 788,691 shares in the IPO, which at the IPO price of $32 would have brought in about $25 million. At the $39.25 market debut price, the firm's remaining stake is worth about $169 million. Bessemer Venture Partners, an investor: $161 million Bessemer Venture Partners backs early-stage and growth-stage startups through venture and private equity investments. The firm has more than 300 companies in its portfolio, according to its website. Bessemer led Hinge Health's $90 million Series C in February 2020. Bessemer partner Elliott Robinson has served on Hinge Health's board of directors since that round. The firm also participated in Hinge Health's $300 million Series D round in January 2021. Bessemer Venture Partners owns about 4.1 million shares, or 5.1% of the company. The firm sold 725,066 shares in the IPO, which at the IPO price of $32 would have brought in about $24 million. At the $39.25 market debut price, its remaining stake is worth about $161 million. Gabriel Mecklenburg, cofounder and executive chairman: $158 million Gabriel Mecklenburg cofounded Hinge Health alongside Perez, personally inspired by the months of physical therapy he completed after tearing his ACL in a judo sparring session. Mecklenburg served as the company's COO for six years. It was a familiar role for him; he'd held the COO title at the two companies he started with Perez before Hinge Health, Oxbridge Biotech Roundtable and Marblar. In 2021, he transitioned to his current role of executive chairman. In addition to his work with Hinge Health, he's served on the board of addiction care startup Pelago since 2022. Mecklenburg owns about 4 million shares, or 4.9% of the company. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $158 million. IP2IPO, an investor: $42 million IP2IPO, named IP2IPO Portfolio LP in Hinge Health's S-1, specializes in moving innovative technologies, talent, and intellectual property from academic institutions to commercial industries. Both Perez and Mecklenburg stepped away from pursuing higher education degrees to build Hinge Health. Perez was taking a leave of absence from a Ph.D. program in biochemistry at the University of Oxford, while Mecklenburg was researching musculoskeletal regenerative medicine at Imperial College London. IP2IPO is a subsidiary of IP Group, a London-based firm that backs breakthrough science and tech companies. IP Group says it's the founding investor in Hinge Health. The firm told BI it actually invested in Marblar, Perez and Mecklenburg's previous startup, back in 2012. That investment rolled over into Hinge Health. "As the UK's leading investor in university spinouts, we met Dan whilst he was in Oxford, working on brilliant ideas and showing real entrepreneurial spirit and tenacity," said Robert Trezona, a partner at IP Group. He said IP Group invested around £1 million, or about $1.12 million at the time, shortly after meeting Perez. IP2IPO owns about 1.1 million shares, or 1.3% of the company. The firm sold about 47,000 shares in the IPO, which at the IPO price of $32 would have brought in about $1.5 million. At the $39.25 market debut price, its remaining stake would be worth about $42 million. Heuristic Capital, an investor: $40 million Early-stage VC firm Heuristic Capital was founded in 2016, and first invested in Hinge Health's seed round that same year. The Santa Clara, California-based firm then invested in Hinge Health's four subsequent raises, from Hinge Health's Series A to its Series D. Heuristic Capital told BI that the Hinge Health team worked out of the firm's San Francisco office in the startup's early days, moving into an independent office in the Bay Area after successfully closing a Series A round. The firm owns about 1 million shares of Hinge Health, or 1.3% of the company. It sold 194,305 shares in the IPO, which at the initial share price of $32 would have brought in about $6.2 million. At the $39.25 market debut price, its remaining stake would be worth about $40 million. Jim Pursley, president: $24 million Longtime digital health executive Jim Pursley joined Hinge Health as its president in 2021. He'd previously worked with the Hinge Health team as an advisor from 2017 to 2019. Pursley came to Hinge Health from Livongo, where he spent six years as the diabetes company's chief commercial officer through its 2019 IPO. He left the company shortly after Livongo announced its $18.5 billion acquisition by Teladoc in 2020. He also held leadership roles at GE Healthcare and Care Innovations, a joint venture between Intel and GE. In addition to his role at Hinge Health, he serves as an independent board member at digital therapeutics company Bodyport. Pursley owns about 604,665 shares. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $24 million. The Vertical Group, an investor: $22 million The Vertical Group, named in Hinge Health's S-1 as Vertical GP-8, is a Basking Ridge, New Jersey-based firm that invests in healthcare and biotech companies. Vertical invested in Hinge Health's seed and Series A funding rounds, according to the firm. The firm told BI that it previously sold a portion of its Hinge Health shares in a secondary transaction in 2021, at $77 a share, and another portion in a 2023 secondary sale, at $36 a share. Vertical is also an investor in diabetes care startup Omada Health, according to the firm's website. Omada is the only other digital health company to file to go public so far this year. Vertical GP-8 owns 554,919 shares. The firm sold about 106,000 shares in the IPO, which at the IPO price of $32 would have brought in about $3.4 million. At the $39.25 market debut price, the firm's remaining stake is worth about $22 million. Jon Reynolds, an angel investor: $14 million Jon Reynolds is the cofounder and former CEO of SwiftKey, the AI-powered keyboard app acquired by Microsoft in 2016. He told BI he first backed Hinge Health that same year, participating in the startup's seed and seed extension funding rounds. Reynolds owned about 360,175 shares. He sold 68,605 shares in the IPO, which at the IPO price of $32 would have brought in about $2.2 million. At the $39.25 market debut price, his remaining stake is worth about $14 million. Industry Ventures, an investor: $12 million San Francisco-based Industry Ventures makes VC bets using flexible capital structures, including secondary transactions and buyouts. Hinge Health has never publicly announced a secondary transaction made by Industry Ventures. Hinge Health's S-1 specifies that Industry Ventures invested in the company through its Secondary IX fund, which the firm announced in March 2021. Industry Ventures didn't respond to a request for comment from BI. Industry Ventures owns 307,259 shares. The firm sold 58,526 shares in the IPO, which at the initial share price of $32 would have brought in about $1.9 million. At the $39.25 market debut price, its remaining stake is worth about $12 million. James Budge, CFO: $6.8 million Serial CFO James Budge joined Hinge Health as its finance chief in 2023. According to his LinkedIn, he's been the CFO of at least eight other companies, spanning industries from workforce software to entertainment tech. He's also served on the board of directors of healthtech company Shadowbox since 2022. Budge owns 172,241 shares. He did not sell any shares in the IPO. At the $39.25 market debut price, his stake is worth about $6.8 million. Kristina Leslie, board member: $343,000 Kristina Leslie joined Hinge Health's board of directors in May 2024 as its audit chair. Leslie, the former CFO of Dreamworks Animation, has spent nearly two decades serving on various company boards, including Glassdoor, CVB Financial Corp., and Rover. According to her LinkedIn, she currently sits on the boards of Sunstone Hotel Investors and Justworks and chairs the board of directors of Blue Shield of California. Leslie owns 8,750 shares. She did not sell any shares in the IPO. At the $39.25 market debut price, her stake is worth about $343,000. Read the original article on Business Insider
Yahoo
20-05-2025
- Business
- Yahoo
Novisto helps companies track their sustainability efforts. Check out the 17-slide deck it used to raise a $27 million Series C.
Novisto has secured $27 million in Series C funding to expand its corporate ESG tracking platform. The platform automates sustainability data management, working with companies like Meta and Sanofi. Check out the 17-slide pitch deck the startup used to secure the fresh funding. A startup that's helping companies track their ESG efforts has just secured a $27 million Series C. Canadian startup Novisto, launched in 2019, offers a software platform for clients to monitor and measure their sustainability impacts. "We have an accounting-like platform for broader sustainability-related data for corporates," cofounder and CEO Charles Assaf told Business Insider. "What is unique about that platform is that it becomes the system of records that really drives not just the reporting and the disclosure exercise, but also the broader management of the sustainability functions," he added. Novisto's platform automates the collection and management of a company's sustainability data — a task that can otherwise be time-consuming if done manually. It then compares a company's ESG efforts according to industry benchmarks and outlines how well itis doing in relation to its competitors, for example. "When your board is requesting specific targets to be tracked, these targets can't sit in an Excel sheet — they have to sit in a system of record that ensures the auditability of that information," Assaf said. "So a lot of companies have proceeded with externally assuring their ESG reports, and we have a mechanism to support this." As an enterprise software startup, Novisto makes its money by charging a monthly subscription fee to clients. Customers include the likes of Meta, JetBlue, and pharma giant Sanofi, among other conglomerates and blue-chip companies. Amid fluctuating attitudes toward ESG policy globally, fueled in part by a change in the US administration, climate tech startups have been facing more headwinds while fundraising. As a result, startups in the sustainability sector have found more opportunities to expand in Europe, where there are more stringent guidelines for ESG reporting. The Series C was led by Inovia Capital, with participation from all previous investors, including White Star Capital, SCOR Ventures, and Sagard. This brings the startup's total funding to $55 million. With the cash injection, Novisto will grow its team in Europe. Check out the pitch deck used to secure the fresh funding. Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
